Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 153

Similar articles for PubMed (Select 23612049)

1.

Factors predictive of outcomes 1 year after 3 monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients.

Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, Ohtsuka H.

Retina. 2013 Oct;33(9):1949-58. doi: 10.1097/IAE.0b013e31828bcafa.

PMID:
23612049
2.

One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients.

Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, Ohtsuka H, Ariga H.

Am J Ophthalmol. 2012 Jul;154(1):117-124.e1. doi: 10.1016/j.ajo.2011.12.019. Epub 2012 Apr 1.

PMID:
22465366
3.

Intravitreal ranibizumab for polypoidal choroidal vasculopathy in non-Asian patients.

Marcus DM, Singh H, Lott MN, Singh J, Marcus MD.

Retina. 2013 Jan;33(1):35-47. doi: 10.1097/IAE.0b013e3182618be0.

PMID:
22990319
4.

Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy.

Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, Ohtsuka H, Kitamei H, Shioya S.

Br J Ophthalmol. 2013 May;97(5):617-21. doi: 10.1136/bjophthalmol-2012-302652. Epub 2013 Feb 21.

5.

Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.

Ricci F, Calabrese A, Regine F, Missiroli F, Ciardella AP.

Retina. 2012 Jul;32(7):1280-8. doi: 10.1097/IAE.0b013e318236e835.

PMID:
22218148
6.

Prognostic factors of 2-year outcomes of ranibizumab therapy for polypoidal choroidal vasculopathy.

Hikichi T, Kitamei H, Shioya S.

Br J Ophthalmol. 2015 Jun;99(6):817-22. doi: 10.1136/bjophthalmol-2014-305606. Epub 2014 Dec 5.

PMID:
25480464
7.

Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.

Kang HM, Koh HJ.

Am J Ophthalmol. 2013 Oct;156(4):652-60. doi: 10.1016/j.ajo.2013.05.038. Epub 2013 Jul 24.

PMID:
23891333
8.

One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.

Cheng CK, Peng CH, Chang CK, Hu CC, Chen LJ.

Retina. 2011 May;31(5):846-56. doi: 10.1097/IAE.0b013e3181f84fdf.

PMID:
21317837
9.

Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.

Lai TY, Lee GK, Luk FO, Lam DS.

Retina. 2011 Sep;31(8):1581-8. doi: 10.1097/IAE.0b013e31820d3f3f.

PMID:
21610566
10.

EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.

Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, Weisberger A, Lim TH.

Retina. 2012 Sep;32(8):1453-64.

PMID:
22426346
11.

Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy.

Gemmy Cheung CM, Yeo I, Li X, Mathur R, Lee SY, Chan CM, Wong D, Wong TY.

Am J Ophthalmol. 2013 Feb;155(2):295-304.e1. doi: 10.1016/j.ajo.2012.08.002. Epub 2012 Oct 27.

PMID:
23111181
12.

Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.

Saito M, Iida T, Kano M, Itagaki K.

Graefes Arch Clin Exp Ophthalmol. 2013 Sep;251(9):2099-110. doi: 10.1007/s00417-013-2323-6. Epub 2013 Apr 5.

PMID:
23553286
13.

Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome.

Ho M, Lo EC, Young AL, Liu DT.

Eye (Lond). 2014 Dec;28(12):1469-76. doi: 10.1038/eye.2014.222. Epub 2014 Sep 26.

PMID:
25257771
14.

Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months.

Hikichi T, Ohtsuka H, Higuchi M, Matsushita T, Ariga H, Kosaka S, Matsushita R, Takami K.

Am J Ophthalmol. 2010 Nov;150(5):674-682.e1. doi: 10.1016/j.ajo.2010.05.026. Epub 2010 Aug 5.

PMID:
20691424
15.

Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results.

Oishi A, Kojima H, Mandai M, Honda S, Matsuoka T, Oh H, Kita M, Nagai T, Fujihara M, Bessho N, Uenishi M, Kurimoto Y, Negi A.

Am J Ophthalmol. 2013 Oct;156(4):644-51. doi: 10.1016/j.ajo.2013.05.024. Epub 2013 Jul 20.

PMID:
23876867
16.

Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.

Sato T, Kishi S, Matsumoto H, Mukai R.

Am J Ophthalmol. 2013 Jul;156(1):95-105.e1. doi: 10.1016/j.ajo.2013.02.006. Epub 2013 Apr 26.

PMID:
23628354
17.

Factors associated with polyp regression after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.

Cho HJ, Han SY, Kim HS, Lee TG, Kim JW.

Jpn J Ophthalmol. 2015 Jan;59(1):29-35. doi: 10.1007/s10384-014-0349-x. Epub 2014 Nov 7.

PMID:
25373450
18.

Correlation of indocyanine green angiography and optical coherence tomography findings after intravitreal ranibizumab for polypoidal choroidal vasculopathy.

Ueno C, Gomi F, Sawa M, Nishida K.

Retina. 2012 Nov-Dec;32(10):2006-13. doi: 10.1097/IAE.0b013e31825c1c31.

PMID:
22772392
19.

Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.

Sagong M, Lim S, Chang W.

Am J Ophthalmol. 2012 May;153(5):873-882.e2. doi: 10.1016/j.ajo.2011.09.031. Epub 2012 Jan 20.

PMID:
22265146
20.

Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.

Saito M, Iida T, Kano M.

Retina. 2012 Jul;32(7):1272-9. doi: 10.1097/IAE.0b013e318236e624.

PMID:
22547209
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk